LTR Pharma Limited (AU:LTP) has released an update.
LTR Pharma Limited reports significant progress in the development of SPONTAN, a promising new nasal spray treatment for Erectile Dysfunction (ED), with the completion of a pivotal clinical study and the production of the first commercial batch. The company, well-funded with a $5.28 million cash balance, is on track to meet its milestones and is gearing up for a potential market shake-up in the global ED treatment landscape. With the study’s results anticipated by mid-2024, LTR Pharma is preparing for regulatory submissions and commercial launch.
For further insights into AU:LTP stock, check out TipRanks’ Stock Analysis page.
